Ruth Alon

330 Avenue Medical Health PC develops, manufactures, and distributes orthopedics and sports medicines. The firm offers treatments include knee pain (osteoarthritis, patello-femoral, meniscal tear, and ligament tear), lower back pain, hip pain (osteoarthritis), and ankle problems (post fractures and recurrent ankle sprain). The company was founded by Avi Elbaz and Amith Mor in 2004 and is headquartered in New York, NY.

CarboFix Orthopedics Ltd. engages in the development, manufacture, and marketing of solutions for trauma and spine. Its products include CarboClear cervical plate, CarboClear pedicle screw, proximal humerus plate, CarboClear lumbar cage, and distal fibula plate. The company was founded Mordechay Beyar in 2011 and is headquartered in Herzliya, Israel.

BrainsGate Ltd. develops medical devices. The firm specializes in therapies for patients suffering from central nervous system diseases. Its platform technology involves electrical stimulation of the Spheno-Palatine Ganglion, a nervous center known to increase cerebral blood flow. The company was founded by Yossi Gross and David Yarnitsky in 2000 and is headquartered in Caesarea, Israel.

Treos Bio Ltd. engages in the development of a digital cancer vaccine technology platform that provides tailored precision vaccines to patients. It focuses on cancer immunotherapies. The company was founded by john Kenneth Hautman and Julianna Lisziewicz in 2013 and is headquartered in London, the United Kingdom.

APOS Medical Israel Ltd. is a holding company that provides non-surgical medical treatment services for musculoskeletal disorders. It offers AposTherapy, a non-surgical and drug-free medical program for knee and back pain, which utilizes an individually calibrated, foot-worn biomechanical device. The firm's program treats body's mal-alignment, muscle weakness, impaired neuromuscular control, and the resulted abnormal pathological movement patterns of orthopaedic conditions. The company was founded by Avi Elbaz and Amit Mor in 2004 and is headquartered in Herzliya Pituach, Israel.

Treos Bio Ltd. engages in the development of a digital cancer vaccine technology platform that provides tailored precision vaccines to patients. It focuses on cancer immunotherapies. The company was founded by john Kenneth Hautman and Julianna Lisziewicz in 2013 and is headquartered in London, the United Kingdom.

Pitango Venture Capital (Pitango) is a venture capital firm founded in 1993 by Rami Kalish. The firm is headquartered in Herzliya, Israel.

Pitango Venture Capital (Pitango) is a venture capital firm founded in 1993 by Rami Kalish. The firm is headquartered in Herzliya, Israel.

APOS Medical Israel Ltd. is a holding company that provides non-surgical medical treatment services for musculoskeletal disorders. It offers AposTherapy, a non-surgical and drug-free medical program for knee and back pain, which utilizes an individually calibrated, foot-worn biomechanical device. The firm's program treats body's mal-alignment, muscle weakness, impaired neuromuscular control, and the resulted abnormal pathological movement patterns of orthopaedic conditions. The company was founded by Avi Elbaz and Amit Mor in 2004 and is headquartered in Herzliya Pituach, Israel.

BrainsGate Ltd. develops medical devices. The firm specializes in therapies for patients suffering from central nervous system diseases. Its platform technology involves electrical stimulation of the Spheno-Palatine Ganglion, a nervous center known to increase cerebral blood flow. The company was founded by Yossi Gross and David Yarnitsky in 2000 and is headquartered in Caesarea, Israel.

Treos Bio Ltd. engages in the development of a digital cancer vaccine technology platform that provides tailored precision vaccines to patients. It focuses on cancer immunotherapies. The company was founded by john Kenneth Hautman and Julianna Lisziewicz in 2013 and is headquartered in London, the United Kingdom.

Pitango Venture Capital (Pitango) is a venture capital firm founded in 1993 by Rami Kalish. The firm is headquartered in Herzliya, Israel.

Pitango Venture Capital (Pitango) is a venture capital firm founded in 1993 by Rami Kalish. The firm is headquartered in Herzliya, Israel.

CarboFix Orthopedics Ltd. engages in the development, manufacture, and marketing of solutions for trauma and spine. Its products include CarboClear cervical plate, CarboClear pedicle screw, proximal humerus plate, CarboClear lumbar cage, and distal fibula plate. The company was founded Mordechay Beyar in 2011 and is headquartered in Herzliya, Israel.

BlueTree Technologies Ltd. is a foodtech company based in Kiryat Shmona, Israel. BlueTree's proprietary technology and system physically and selectively reduces sugar content (up to 50%%) from 100%% squeezed natural orange juice, making it natural, healthy, and tasty. The Israeli company's technology and system offer several significant benefits to the natural juice industry, including reduced sugar, improved blending properties, and improved reduced storage and distribution. BlueTree is the first "graduate" of the FreshStart Food Tech Incubator, partnered by Tnuva, Tempo, OurCrowd, and Finistere Ventures, and is one of the leading players in the thriving northern food tech ecosystem. The company was founded by Yuval Klein and Didier Toubia, and Michael Gordon has been the CEO of the company since 2022.

Pitango Venture Capital (Pitango) is a venture capital firm founded in 1993 by Rami Kalish. The firm is headquartered in Herzliya, Israel.

CarboFix Orthopedics Ltd. engages in the development, manufacture, and marketing of solutions for trauma and spine. Its products include CarboClear cervical plate, CarboClear pedicle screw, proximal humerus plate, CarboClear lumbar cage, and distal fibula plate. The company was founded Mordechay Beyar in 2011 and is headquartered in Herzliya, Israel.

BrainsGate Ltd. develops medical devices. The firm specializes in therapies for patients suffering from central nervous system diseases. Its platform technology involves electrical stimulation of the Spheno-Palatine Ganglion, a nervous center known to increase cerebral blood flow. The company was founded by Yossi Gross and David Yarnitsky in 2000 and is headquartered in Caesarea, Israel.

BrainsGate Ltd. develops medical devices. The firm specializes in therapies for patients suffering from central nervous system diseases. Its platform technology involves electrical stimulation of the Spheno-Palatine Ganglion, a nervous center known to increase cerebral blood flow. The company was founded by Yossi Gross and David Yarnitsky in 2000 and is headquartered in Caesarea, Israel.

Phoska Biopharma Pte Ltd. develops advancing new therapies for treating liver and metabolic conditions. The company is headquartered in Singapore.

APOS Medical Israel Ltd. is a holding company that provides non-surgical medical treatment services for musculoskeletal disorders. It offers AposTherapy, a non-surgical and drug-free medical program for knee and back pain, which utilizes an individually calibrated, foot-worn biomechanical device. The firm's program treats body's mal-alignment, muscle weakness, impaired neuromuscular control, and the resulted abnormal pathological movement patterns of orthopaedic conditions. The company was founded by Avi Elbaz and Amit Mor in 2004 and is headquartered in Herzliya Pituach, Israel.

330 Avenue Medical Health PC develops, manufactures, and distributes orthopedics and sports medicines. The firm offers treatments include knee pain (osteoarthritis, patello-femoral, meniscal tear, and ligament tear), lower back pain, hip pain (osteoarthritis), and ankle problems (post fractures and recurrent ankle sprain). The company was founded by Avi Elbaz and Amith Mor in 2004 and is headquartered in New York, NY.

Fibronostics US, Inc. operates healthcare technology company, which develops algorithms to detect disease and monitor progression. The firm provides platform that develops non-invasive algorithm based diagnostics to improve treatment outcomes, facilitate screening of specific diseases and help prognosis in various chronic conditions. The company was founded in 2015 and is headquartered in Orlando, FL.

Pitango Venture Capital (Pitango) is a venture capital firm founded in 1993 by Rami Kalish. The firm is headquartered in Herzliya, Israel.

APOS Medical Israel Ltd. is a holding company that provides non-surgical medical treatment services for musculoskeletal disorders. It offers AposTherapy, a non-surgical and drug-free medical program for knee and back pain, which utilizes an individually calibrated, foot-worn biomechanical device. The firm's program treats body's mal-alignment, muscle weakness, impaired neuromuscular control, and the resulted abnormal pathological movement patterns of orthopaedic conditions. The company was founded by Avi Elbaz and Amit Mor in 2004 and is headquartered in Herzliya Pituach, Israel.

Treos Bio Ltd. engages in the development of a digital cancer vaccine technology platform that provides tailored precision vaccines to patients. It focuses on cancer immunotherapies. The company was founded by john Kenneth Hautman and Julianna Lisziewicz in 2013 and is headquartered in London, the United Kingdom.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

APOS Medical Israel Ltd. is a holding company that provides non-surgical medical treatment services for musculoskeletal disorders. It offers AposTherapy, a non-surgical and drug-free medical program for knee and back pain, which utilizes an individually calibrated, foot-worn biomechanical device. The firm's program treats body's mal-alignment, muscle weakness, impaired neuromuscular control, and the resulted abnormal pathological movement patterns of orthopaedic conditions. The company was founded by Avi Elbaz and Amit Mor in 2004 and is headquartered in Herzliya Pituach, Israel.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Treos Bio Ltd. engages in the development of a digital cancer vaccine technology platform that provides tailored precision vaccines to patients. It focuses on cancer immunotherapies. The company was founded by john Kenneth Hautman and Julianna Lisziewicz in 2013 and is headquartered in London, the United Kingdom.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Pitango Venture Capital (Pitango) is a venture capital firm founded in 1993 by Rami Kalish. The firm is headquartered in Herzliya, Israel.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

BrainsGate Ltd. develops medical devices. The firm specializes in therapies for patients suffering from central nervous system diseases. Its platform technology involves electrical stimulation of the Spheno-Palatine Ganglion, a nervous center known to increase cerebral blood flow. The company was founded by Yossi Gross and David Yarnitsky in 2000 and is headquartered in Caesarea, Israel.

Pitango Venture Capital (Pitango) is a venture capital firm founded in 1993 by Rami Kalish. The firm is headquartered in Herzliya, Israel.

330 Avenue Medical Health PC develops, manufactures, and distributes orthopedics and sports medicines. The firm offers treatments include knee pain (osteoarthritis, patello-femoral, meniscal tear, and ligament tear), lower back pain, hip pain (osteoarthritis), and ankle problems (post fractures and recurrent ankle sprain). The company was founded by Avi Elbaz and Amith Mor in 2004 and is headquartered in New York, NY.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Pitango Venture Capital (Pitango) is a venture capital firm founded in 1993 by Rami Kalish. The firm is headquartered in Herzliya, Israel.

Pitango Venture Capital (Pitango) is a venture capital firm founded in 1993 by Rami Kalish. The firm is headquartered in Herzliya, Israel.

Pitango Venture Capital (Pitango) is a venture capital firm founded in 1993 by Rami Kalish. The firm is headquartered in Herzliya, Israel.

BrainsGate Ltd. develops medical devices. The firm specializes in therapies for patients suffering from central nervous system diseases. Its platform technology involves electrical stimulation of the Spheno-Palatine Ganglion, a nervous center known to increase cerebral blood flow. The company was founded by Yossi Gross and David Yarnitsky in 2000 and is headquartered in Caesarea, Israel.

BrainsGate Ltd. develops medical devices. The firm specializes in therapies for patients suffering from central nervous system diseases. Its platform technology involves electrical stimulation of the Spheno-Palatine Ganglion, a nervous center known to increase cerebral blood flow. The company was founded by Yossi Gross and David Yarnitsky in 2000 and is headquartered in Caesarea, Israel.

BrainsGate Ltd. develops medical devices. The firm specializes in therapies for patients suffering from central nervous system diseases. Its platform technology involves electrical stimulation of the Spheno-Palatine Ganglion, a nervous center known to increase cerebral blood flow. The company was founded by Yossi Gross and David Yarnitsky in 2000 and is headquartered in Caesarea, Israel.

BrainsGate Ltd. develops medical devices. The firm specializes in therapies for patients suffering from central nervous system diseases. Its platform technology involves electrical stimulation of the Spheno-Palatine Ganglion, a nervous center known to increase cerebral blood flow. The company was founded by Yossi Gross and David Yarnitsky in 2000 and is headquartered in Caesarea, Israel.

Pitango Venture Capital (Pitango) is a venture capital firm founded in 1993 by Rami Kalish. The firm is headquartered in Herzliya, Israel.

BrainsGate Ltd. develops medical devices. The firm specializes in therapies for patients suffering from central nervous system diseases. Its platform technology involves electrical stimulation of the Spheno-Palatine Ganglion, a nervous center known to increase cerebral blood flow. The company was founded by Yossi Gross and David Yarnitsky in 2000 and is headquartered in Caesarea, Israel.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

BrainsGate Ltd. develops medical devices. The firm specializes in therapies for patients suffering from central nervous system diseases. Its platform technology involves electrical stimulation of the Spheno-Palatine Ganglion, a nervous center known to increase cerebral blood flow. The company was founded by Yossi Gross and David Yarnitsky in 2000 and is headquartered in Caesarea, Israel.

Treos Bio Ltd. engages in the development of a digital cancer vaccine technology platform that provides tailored precision vaccines to patients. It focuses on cancer immunotherapies. The company was founded by john Kenneth Hautman and Julianna Lisziewicz in 2013 and is headquartered in London, the United Kingdom.

APOS Medical Israel Ltd. is a holding company that provides non-surgical medical treatment services for musculoskeletal disorders. It offers AposTherapy, a non-surgical and drug-free medical program for knee and back pain, which utilizes an individually calibrated, foot-worn biomechanical device. The firm's program treats body's mal-alignment, muscle weakness, impaired neuromuscular control, and the resulted abnormal pathological movement patterns of orthopaedic conditions. The company was founded by Avi Elbaz and Amit Mor in 2004 and is headquartered in Herzliya Pituach, Israel.

330 Avenue Medical Health PC develops, manufactures, and distributes orthopedics and sports medicines. The firm offers treatments include knee pain (osteoarthritis, patello-femoral, meniscal tear, and ligament tear), lower back pain, hip pain (osteoarthritis), and ankle problems (post fractures and recurrent ankle sprain). The company was founded by Avi Elbaz and Amith Mor in 2004 and is headquartered in New York, NY.